Ecleralimab (anti-TSLP) is a novel inhaled anti-TSLP that in a phase IIa proof-of-concept study, was well tolerated and reduced allergen-induced bronchoconstriction in adults with mild asthma. This evidence concerns the gene TSLP and asthma.